Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing
quadruple therapy was suggested to be the first choice for eradication therapy of
Helicobacter pylori in the area with high clarithromycin resistance. Whether hybrid therapy
or 14-day bismuth containing quadruple therapy can replace standard triple therapy as the
recommended first-line treatment is unknown. The investigators compared the efficacy of
14-day hybrid therapy and 14-day bismuth containing quadruple therapy in first-line
treatment.